Pompe Disease Market in the US 2015-2019
About pompe disease
Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action of GAA, an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen in the lysosomes of the cells. The buildup of glycogen in certain organs and tissues, especially in the muscles, hinders the normal functions of the organs. Pompe disease can be further classified as infantile-onset and adult-onset Pompe disease. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and can pass one copy of the mutated gene to their offspring. The disease affects both men and women.
Technavio's analysts forecast the pompe disease market in the US to grow at a CAGR of 10.68 % over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the pompe disease market in US for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of the drugs available in the US market and the drug candidates that are in various phases of development for the treatment of Pompe disease.
The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Technavio's report, Pompe Disease Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It also covers the landscape of the market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Pompe Disease Market in US 2015-2019
Technavio recognizes the following companies as the key players in the Pompe Disease Market in US: Amicus Therapeutics, BioMarin Pharmaceutical and Genzyme
Other Prominent Vendors in the market are: Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, and Valerion Therapeutics.
Commenting on the report, an analyst from Technavio’s team said: “The market is expected to witness certain emerging trends. The rise in awareness programs to treat Pompe disease patients is one such trend. It increases the treatment seeking rate among patients, which results in an increase in overall consumption of medicines.”
According to the report, the special provision for orphan drugs given by the FDA in terms of market exclusivity and tax benefits for a specified time, is one factor. Also, the presence of high unmet needs for appropriate drugs is another major factor propelling the growth of the market.
Further, the report states that the limited patient population is a major factor hindering the growth of the market. It is known to hamper the clinical studies of a drug candidate under development for the treatment of Pompe disease.
Amicus Therapeutics, BioMarin Pharmaceutical, Genzyme, Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, Valerion Therapeutics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook